Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
Saved in:
| Title: | Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). |
|---|---|
| Authors: | Saura, C.1 (AUTHOR) csaura@vhio.net, Modi, S.2 (AUTHOR), Krop, I.3 (AUTHOR), Park, Y.H.4 (AUTHOR), Kim, S.-B.5 (AUTHOR), Tamura, K.6 (AUTHOR), Iwata, H.7 (AUTHOR), Tsurutani, J.8 (AUTHOR), Sohn, J.9 (AUTHOR), Mathias, E.10 (AUTHOR), Liu, Y.10 (AUTHOR), Cathcart, J.10 (AUTHOR), Singh, J.10 (AUTHOR), Yamashita, T.11 (AUTHOR) |
| Source: | Annals of Oncology. Mar2024, Vol. 35 Issue 3, p302-307. 6p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.12.001 |
